Level C· Early human research exploring benefitsProspective StudyPubMed

[Effect of human adipose-derived stem cells on pressure ulcer healing in mouse].

Deng C., Liu Z., Yao Y., Liu R., Wei Z., Wang D.

Prospective Study with a reported sample of 15 on Chronic Wound, published in Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2018) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2018)
Country
China
Reported sample size
15
Source database
PubMed
PMID
29905053
PMCID
PMC8414016
DOI
10.7507/1002-1892.201801031

Abstract (original English)

To investigate the effect of human adipose-derived stem cells (hADSCs) on pressure ulcers in mouse. The subcutaneous adipose tissue from voluntary donation was harvested. Then the hADSCs were isolated and cultured by mechanical isolation combined with typeⅠcollagenase digestion. The 3rd generation cells were identified by osteogenic, adipogenic, chondrogenic differentiations and flow cytometry. The platelet rich plasma (PRP) from peripheral blood donated by healthy volunteers was prepared by centrifugation. The pressure ulcer model was established in 45 C57BL/6 mice by two magnets pressurized the back skin, and randomly divided into 3 groups ( n =15). The wounds were injected with 100 μL of hADSCs (1×10 6 cells) transfected with a green fluorescent protein (GFP)-carrying virus, 100 μL human PRP, and 100 μL PBS in hADSCs group, PRP group, and control group, respectively. The wound healing was observed after injection. The wound healing rate was calculated on the 5th, 9th, and 13th days. On the 5th, 11th, and 21st day, the specimens were stained with HE staing, Masson staining, and CD31 and S100 immunohistochemical staining to observe the vascular and nerve regeneration of the wound. In hADSCs group, fluorescence tracer method was used to observe the colonization and survival of the cells on the 11th day. The cultured cells were identified as hADSCs by induced differentiation and

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdipocytesAnimalsHumansMiceMice, Inbred C57BLPressure UlcerStem CellsWound Healing

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research